Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma
Phase I Safety Study Of 131I-Lym-1 For The Treatment Of Previously Treated Diffuse Large B-Cell Lymphoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances such as radioactive iodine to them without harming normal cells.
PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibodies in treating patients who have large cell lymphoma that has been previously treated.
調査の概要
詳細な説明
OBJECTIVES:
- Determine the maximum tolerated dose of iodine I 131 monoclonal antibody Lym-1 in patients with previously treated diffuse large cell lymphoma.
- Determine the safety of this drug in these patients.
- Determine the response of patients to this drug.
OUTLINE: This is a dose-escalation, multicenter study.
Patients receive unlabeled monoclonal antibody Lym-1 IV over 40 minutes followed 15-30 minutes later by iodine I 131 monoclonal antibody Lym-1 IV over 2 minutes.
Cohorts of 3-6 patients receive escalating doses of iodine I 131 monoclonal antibody Lym-1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed weekly for 8 weeks and then every 3 months for 1 year.
PROJECTED ACCRUAL: A total of 8-36 patients will be accrued for this study.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106-5065
- Ireland Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
- Histologic diagnosis of B-cell diffuse large cell lymphoma (REAL classification system) confirmed by an independent central pathology reviewer.
- The tumor's B-cell phenotype will be confirmed by positive L-26 (CD20).
- Previous treatment with 2 common combination chemotherapy regimens. Patients previously treated with unlabeled monoclonal antibody therapy are eligible.
- Men or women at least 18 years of age.
- Karnofsky Performance Score (KPS) estimated to be > 60 at the time of the scheduled therapeutic dose of 131I-Lym-1.
- Life expectancy estimated to be at least 3 months from the time of the therapeutic dose of 131I Lym-1.
- Measurable disease demonstrable by physical examination or computerized tomography (CT).
- CT scan evidence of at least one indicator lesion with at least one diameter that measures > 2 cm. (The CT scan should be done within 2 weeks of the imaging study.)
Exclusion Criteria
- Inability or unwillingness to comply with the following:
- Bone marrow biopsy
- Return for follow-up visits
- Remaining motionless for extended periods of time for imaging procedures
- Serial blood/urine sampling (for dosimetry patients only)
- Pregnancy (Women of childbearing potential must be practicing an effective method of contraception.)
- Presence of a second malignancy except for basal cell skin carcinoma or carcinoma in-situ of the cervix
- Presence of active lymphomatous meningitis or other CNS involvement with lymphoma.
- HIV positive patients.
- Prior total body irradiation, or a course of prior radiation > 3,000 cGy delivered to > 20% of the central marrow or the lumbar vertebrae within 6 months of screening.
- Serum creatinine or total bilirubin > 2 x the upper limit of normal.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase > 3 x the upper limit of normal.
- Significant marrow lymphoma (defined as lymphoma cells constituting greater than 20% of the hematopoietic marrow elements from an iliac crest biopsy). A prior bone marrow biopsy is acceptable if it meets the following criteria:
- If there is prior bone marrow involvement, the biopsy must be performed within 45 days of screening.
- If there is no prior bone marrow involvement, the biopsy must be performed within 90 days of screening
- WBC count < 3,500/mm3, granulocyte count < 1,500/mm3, or platelet count < 125,000/mm3.
- Positive human anti-mouse antibodies (HAMA) serum values, defined as > 74 ng/mL at screening.
- Patients who have not recovered from toxicities of most recent anti-lymphoma therapy.
- Treatment with:
- Colony stimulating factor G-CSF or GM-CSF within 120 hours of screening laboratory assessment.
- Erythropoietin (EPO) within a month of screening laboratory assessment
- Whole blood or platelet transfusion within 120 hours of screening laboratory assessment
- History or electrocardiographic (ECG) evidence of Q-wave myocardial infarction within 6 months of screening or congestive heart failure (CHF; NYHA Stage III or IV).
- Known hypersensitivity to iodine or iodine-containing organic substances.
- Patients who require therapy with anticoagulants or antiplatelet drugs which cannot be discontinued during the study.
- Patients who are known to have antiplatelet antibodies.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
協力者と研究者
捜査官
- スタディチェア:Omer N. Koc, MD、Case Comprehensive Cancer Center
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
iodine I 131 monoclonal antibody Lym-1の臨床試験
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)積極的、募集していない再発甲状腺がん | 低分化型甲状腺がん | ステージ IV 甲状腺濾胞癌 AJCC v7 | ステージ IV 甲状腺乳頭癌 AJCC v7 | ステージ IVA 甲状腺濾胞癌 AJCC v7 | ステージ IVA 甲状腺乳頭癌 AJCC v7 | ステージ IVB 甲状腺濾胞癌 AJCC v7 | ステージ IVB 甲状腺乳頭癌 AJCC v7 | ステージ IVC 甲状腺濾胞癌 AJCC v7 | ステージ IVC 甲状腺乳頭癌 AJCC v7 | 転移性甲状腺癌アメリカ
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)完了粘膜関連リンパ組織の節外縁帯B細胞リンパ腫 | 節性辺縁帯B細胞リンパ腫 | 再発成人バーキットリンパ腫 | 再発成人びまん性大細胞型リンパ腫 | 再発成人びまん性混合細胞リンパ腫 | 再発成人びまん性小細胞分裂型リンパ腫 | 再発成人免疫芽球性大細胞型リンパ腫 | 再発成人リンパ芽球性リンパ腫 | 再発グレード1の濾胞性リンパ腫 | 再発グレード2濾胞性リンパ腫 | 再発グレード 3 濾胞性リンパ腫 | 再発マントル細胞リンパ腫 | 再発辺縁帯リンパ腫 | 脾辺縁帯リンパ腫 | ワルデンストレームマクログロブリン血症 | 未分化大細胞型リンパ腫 | 皮膚B細胞非ホジキンリンパ腫アメリカ
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)終了しました以前の骨髄異形成症候群に起因する急性骨髄性白血病 | 慢性骨髄単球性白血病 | 治療歴のある骨髄異形成症候群 | 寛解期の成人急性骨髄性白血病 | 寛解期の成人急性リンパ芽球性白血病 | 過剰芽球を伴う不応性貧血 | 環状鉄芽球を伴う不応性貧血 | 多系統異形成を伴う難治性血球減少症 | 多系統異形成および環状鉄芽球を伴う難治性血球減少症 | CD45陽性腫瘍細胞の存在アメリカ
-
Children's Oncology GroupNational Cancer Institute (NCI)積極的、募集していない
-
Children's Oncology GroupNational Cancer Institute (NCI)積極的、募集していない限局性切除可能神経芽腫 | 限局性切除不能神経芽腫 | 局所神経芽腫 | ステージ 4S 神経芽細胞腫 | 神経節芽細胞腫 | ステージ 4 神経芽細胞腫アメリカ
-
Memorial Sloan Kettering Cancer CenterGlaxoSmithKline完了